AbbottABT
ABT
About: Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Employees: 114,000
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 12 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
14% more first-time investments, than exits
New positions opened: 186 | Existing positions closed: 163
9% more funds holding in top 10
Funds holding in top 10: 58 [Q2] → 63 (+5) [Q3]
6% more call options, than puts
Call options by funds: $1.1B | Put options by funds: $1.04B
4% more capital invested
Capital invested by funds: $141B [Q2] → $147B (+$5.65B) [Q3]
1% more funds holding
Funds holding: 2,811 [Q2] → 2,834 (+23) [Q3]
3.97% less ownership
Funds ownership: 77.9% [Q2] → 73.94% (-3.97%) [Q3]
11% less repeat investments, than reductions
Existing positions increased: 1,049 | Existing positions reduced: 1,177
Research analyst outlook
12 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$117
2%
upside
Avg. target
$131
15%
upside
High target
$149
30%
upside
12 analyst ratings
8 positive
67%
4 neutral
33%
0 negative
0%
Barclays Matt Miksic 61% 1-year accuracy 22 / 36 met price target | 30%upside $149 | Overweight Maintained | 5 Nov 2024 |
Bernstein Lee Hambright 50% 1-year accuracy 3 / 6 met price target | 21%upside $138 | Outperform Maintained | 17 Oct 2024 |
UBS Danielle Antalffy 38% 1-year accuracy 5 / 13 met price target | 28%upside $146 | Buy Maintained | 17 Oct 2024 |
Jefferies Matthew Taylor 50% 1-year accuracy 2 / 4 met price target | 9%upside $125 | Hold Maintained | 17 Oct 2024 |
Mizuho Anthony Petrone 39% 1-year accuracy 15 / 38 met price target | 14%upside $130 | Neutral Maintained | 17 Oct 2024 |
Financial journalist opinion
Based on 27 articles about ABT published over the past 30 days
Positive
Seeking Alpha
4 hours ago
Abbott Laboratories: A Future-Driven Pharma Brand With A Robust Pipeline
Abbott Laboratories: A Future-Driven Pharma Brand With A Robust Pipeline
Positive
The Motley Fool
5 hours ago
My Top 10 Stocks to Buy for 2025
It's that time of year again. I'm not referring to buying gifts and preparing holiday meals -- although that may be part of your agenda too.
Positive
Zacks Investment Research
1 day ago
4 Healthcare Technology Innovators to Invest in Before the New Year
Here, we have presented four healthcare technology stocks for stable portfolio gains in 2025: VCYT, OMCL, MASI and ABT.
Positive
Zacks Investment Research
1 day ago
Reasons to Retain ABT Stock in Your Portfolio Now
Investors feel optimistic about Abbott's robust strength in the EPD and Nutrition businesses. Yet, unfavorable forex impacts are concerning.
Positive
The Motley Fool
2 days ago
2 Top Dividend Stocks to Buy and Hold Through 2025 and Beyond
What will be the hottest investing trend on Wall Street next year? Maybe artificial intelligence will keep up its momentum, or perhaps interest in weight loss-focused pharmaceutical companies will increase.
Positive
Zacks Investment Research
3 days ago
ABT Stock Up on First Successful LBBAP Procedures With AVEIR Pacemaker
Abbott completes the world's first leadless pacing procedures in the left bundle branch of the heart.
Positive
The Motley Fool
3 days ago
The Smartest Dividend Stocks to Buy With $500 Right Now
As an investor, your goal is to select quality stocks that will advance over a period of years -- but this doesn't mean you have to wait a long time for all of the rewards. If you add a few dividend stocks to your portfolio, you'll start collecting returns on a regular basis -- without lifting a finger.
Negative
Zacks Investment Research
3 days ago
Abbott (ABT) Increases Despite Market Slip: Here's What You Need to Know
In the latest trading session, Abbott (ABT) closed at $113.29, marking a +0.59% move from the previous day.
Neutral
PRNewsWire
4 days ago
Abbott Announces First-in-World Leadless Pacing Procedures in the Left Bundle Branch Area of the Heart
Abbott's investigational AVEIR™ Conduction System Pacing (CSP) leadless pacemaker system is specifically designed to deliver pacing to the left bundle branch area, activating the heart's natural conduction system The device has received U.S. Food and Drug Administration Breakthrough Device Designation, which expedites the review of innovative technologies By creating a new pacing approach for the left bundle branch area of the heart, Abbott continues to pursue technologies to revolutionize care for people with slow or irregular heart rhythms ABBOTT PARK, Ill., Dec. 17, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) today announced the successful completion of the world's first in-human leadless left bundle branch area pacing (LBBAP) procedures using the company's investigational AVEIR™ Conduction System Pacing (CSP) leadless pacemaker system, as part of a feasibility study.
Positive
Seeking Alpha
1 week ago
Best Way To Invest $100,000: Build An 8-Stock Portfolio For Growth And Value
Concentrate on a select few high-conviction stocks across different sectors to avoid "diworsification" and maximize returns, inspired by Charlie Munger and Warren Buffett. Utilize Joel Greenblatt's "Magic Formula" and James O'Shaughnessy's methodologies to screen stocks based on earnings yield and return on total capital. Exclude overly regulated sectors like Utilities, Financials, and REITs to focus on sectors with higher growth potential and less regulatory constraints.
Charts implemented using Lightweight Charts™